Symbols / TRAW $2.20 +4.27%
TRAW Chart
About
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small-molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza. It is also developing narazaciclib, a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and rigosertib, which is administered alone or in combination for investigation in various cancers. It has a license agreement with SymBio Pharmaceuticals Limited, Pint International SA, Viriom, Inc., and Temple University. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 17.58M |
| Enterprise Value | 11.16M | Income | -9.16M | Sales | 2.85M |
| Book/sh | 0.64 | Cash/sh | 0.80 | Dividend Yield | — |
| Payout | 0.00% | Employees | 6 | IPO | — |
| P/E | — | Forward P/E | -0.51 | PEG | — |
| P/S | 6.18 | P/B | 3.45 | P/C | — |
| EV/EBITDA | -0.71 | EV/Sales | 3.92 | Quick Ratio | 1.07 |
| Current Ratio | 1.22 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -1.82 | EPS next Y | -4.32 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-13 07:00 | ROA | -92.29% |
| ROE | -10.60% | ROIC | — | Gross Margin | 100.00% |
| Oper. Margin | -5.55% | Profit Margin | 0.00% | Shs Outstand | 7.99M |
| Shs Float | 3.80M | Short Float | 11.64% | Short Ratio | 3.05 |
| Short Interest | — | 52W High | 3.27 | 52W Low | 0.97 |
| Beta | 1.76 | Avg Volume | 212.66K | Volume | 78.98K |
| Target Price | $7.25 | Recom | None | Prev Close | $2.11 |
| Price | $2.20 | Change | 4.27% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$7.25
Mean price target
2. Current target
$2.20
Latest analyst target
3. DCF / Fair value
$-26.69
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.20
Low
$6.50
High
$8.00
Mean
$7.25
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-03 | init | HC Wainwright & Co. | — → Buy | $8 |
- TRAW Stock Slides In Volatile Session – What’s The Latest On Its Phase 2 Trial For COVID-19 Treatment? - Stocktwits Mon, 26 Jan 2026 08
- New COVID pill shows fewer side effects than Paxlovid in early test - Stock Titan Wed, 17 Dec 2025 08
- Resistance Check: Is TRAW a cyclical or defensive stock - Trade Risk Summary & Free Accurate Trade Setup Notifications - baoquankhu1.vn Wed, 18 Mar 2026 05
- Is Traws Pharma Stock Built to Withstand More Downside? - Trefis ue, 23 Dec 2025 08
- Traws Pharma (TRAW) awards 33,435 stock options to director Jack Stover - Stock Titan ue, 10 Mar 2026 23
- TRAW | Traws Pharma, Inc. Common Institutional Ownership - Quiver Quantitative Mon, 29 Sep 2025 03
- Traws Pharma stock soars after completing COVID-19 treatment study - Investing.com Mon, 26 Jan 2026 08
- CBSTF Technical Analysis & Stock Price Forecast - Intellectia AI Sun, 15 Mar 2026 20
- Traws Pharma, Inc. SEC 10-Q Report - TradingView hu, 13 Nov 2025 08
- Traws Pharma (TRAW) CMO awarded 108,854 stock options at $1.60 - Stock Titan ue, 10 Mar 2026 23
- Traws Pharma Reports Promising Interim Data for Ratutrelvir, Showing Favorable Profile Compared to PAXLOVID™ in COVID-19 Treatment - Quiver Quantitative Wed, 17 Dec 2025 08
- Director at Traws Pharma (TRAW) receives grant of 33,435 stock options - Stock Titan ue, 10 Mar 2026 23
- Traws Pharma (TRAW) awards 118,367 stock options to Chief Science Officer - Stock Titan ue, 10 Mar 2026 23
- TRAW - Traws Pharma Latest Stock News & Market Updates - Stock Titan Mon, 26 Jan 2026 08
- TRAW - Traws Pharma Latest Stock News & Market Updates - Stock Titan Sun, 22 Feb 2026 16
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 16419 | — | — | Stock Award(Grant) at price 0.00 per share. | SAVCHUK NIKOLAY | Chief Operating Officer | — | 2025-12-12 00:00:00 | D |
| 1 | 6157 | — | — | Stock Award(Grant) at price 0.00 per share. | STOVER JACK E | Director | — | 2025-12-12 00:00:00 | D |
| 2 | 4058 | — | — | Stock Award(Grant) at price 0.00 per share. | LEAMAN JOHN HAROLD | Director | — | 2025-12-12 00:00:00 | D |
| 3 | 36943 | — | — | Stock Award(Grant) at price 0.00 per share. | DUKES IAIN D | Chief Executive Officer | — | 2025-12-12 00:00:00 | D |
| 4 | 6157 | — | — | Stock Award(Grant) at price 0.00 per share. | SHOEMAKER MARY TERESA | Director | — | 2025-12-12 00:00:00 | D |
| 5 | 6157 | — | — | Stock Award(Grant) at price 0.00 per share. | CLARKE TRAFFORD PH.D. | Director | — | 2025-12-12 00:00:00 | D |
| 6 | 18471 | — | — | Stock Award(Grant) at price 0.00 per share. | PAUZA CHARLES DAVID | Officer | — | 2025-12-12 00:00:00 | D |
| 7 | 4874 | — | — | Stock Award(Grant) at price 0.00 per share. | CAUTREELS WERNER C | Director | — | 2025-12-12 00:00:00 | D |
| 8 | 16419 | — | — | Stock Award(Grant) at price 0.00 per share. | REDFIELD ROBERT | Officer | — | 2025-12-12 00:00:00 | D |
| 9 | 96348 | 963.0 | — | Conversion of Exercise of derivative security at price 0.01 per share. | CAUTREELS WERNER C | Chief Executive Officer | — | 2025-02-18 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | 117.00M | -20.28M | -19.61M | -16.80M |
| TotalUnusualItems | -141.90M | 0.00 | 321.00K | |
| TotalUnusualItemsExcludingGoodwill | -141.90M | 0.00 | 321.00K | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -166.52M | -18.95M | -18.96M | -16.16M |
| ReconciledDepreciation | 12.00K | 16.00K | 14.00K | 14.00K |
| EBITDA | -24.90M | -20.28M | -19.61M | -16.48M |
| EBIT | -24.91M | -20.30M | -19.63M | -16.50M |
| NormalizedIncome | -24.62M | -18.95M | -18.96M | -16.48M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -166.52M | -18.95M | -18.96M | -16.16M |
| TotalExpenses | 25.14M | 20.52M | 19.85M | 16.72M |
| TotalOperatingIncomeAsReported | -142.37M | -20.30M | -19.63M | -16.50M |
| DilutedAverageShares | 1.55M | 839.55K | 836.33K | 673.29K |
| BasicAverageShares | 1.55M | 839.55K | 836.33K | 673.29K |
| DilutedEPS | -35.21 | -22.57 | -22.75 | -24.00 |
| BasicEPS | -35.21 | -22.57 | -22.75 | -24.00 |
| DilutedNIAvailtoComStockholders | -54.67M | -18.95M | -18.96M | -16.16M |
| NetIncomeCommonStockholders | -54.67M | -18.95M | -18.96M | -16.16M |
| PreferredStockDividends | -111.85M | |||
| NetIncome | -166.52M | -18.95M | -18.96M | -16.16M |
| NetIncomeIncludingNoncontrollingInterests | -166.52M | -18.95M | -18.96M | -16.16M |
| NetIncomeContinuousOperations | -166.52M | -18.95M | -18.96M | -16.16M |
| TaxProvision | 0.00 | |||
| PretaxIncome | -166.52M | -18.95M | -18.96M | -16.16M |
| OtherIncomeExpense | -141.61M | 1.35M | 663.00K | 333.00K |
| OtherNonOperatingIncomeExpenses | 289.00K | 1.35M | 663.00K | 12.00K |
| SpecialIncomeCharges | -117.46M | 0.00 | ||
| OtherSpecialCharges | 117.46M | |||
| GainOnSaleOfSecurity | -24.44M | 321.00K | ||
| OperatingIncome | -24.91M | -20.30M | -19.63M | -16.50M |
| OperatingExpense | 25.14M | 20.52M | 19.85M | 16.72M |
| ResearchAndDevelopment | 12.85M | 11.43M | 11.41M | 7.30M |
| SellingGeneralAndAdministration | 12.29M | 9.09M | 8.45M | 9.43M |
| GeneralAndAdministrativeExpense | 12.29M | 9.09M | 8.45M | 9.43M |
| OtherGandA | 7.18M | 4.13M | 3.21M | 4.34M |
| InsuranceAndClaims | 860.00K | 985.00K | 1.29M | 1.42M |
| SalariesAndWages | 4.24M | 3.98M | 3.95M | 3.67M |
| TotalRevenue | 226.00K | 226.00K | 226.00K | 226.00K |
| OperatingRevenue | 226.00K | 226.00K | 226.00K | 226.00K |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 3.65M | 840.14K | 837.04K | 835.82K |
| ShareIssued | 3.65M | 840.14K | 837.04K | 835.82K |
| TangibleBookValue | -31.63M | 10.67M | 28.31M | 46.12M |
| InvestedCapital | -31.63M | 10.67M | 28.31M | 46.12M |
| WorkingCapital | 13.42M | 13.44M | 31.30M | 49.31M |
| NetTangibleAssets | -31.63M | 10.67M | 28.31M | 46.12M |
| CommonStockEquity | -31.63M | 10.67M | 28.31M | 46.12M |
| TotalCapitalization | -31.63M | 10.67M | 28.31M | 46.12M |
| TotalEquityGrossMinorityInterest | -31.63M | 10.67M | 28.31M | 46.12M |
| StockholdersEquity | -31.63M | 10.67M | 28.31M | 46.12M |
| GainsLossesNotAffectingRetainedEarnings | -42.00K | -23.00K | -33.00K | -14.00K |
| OtherEquityAdjustments | -42.00K | -23.00K | -33.00K | -14.00K |
| RetainedEarnings | -649.15M | -482.63M | -463.68M | -444.72M |
| AdditionalPaidInCapital | 617.53M | 493.32M | 491.82M | 490.64M |
| CapitalStock | 36.00K | 9.00K | 209.00K | 209.00K |
| CommonStock | 36.00K | 9.00K | 209.00K | 209.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 56.59M | 12.01M | 11.06M | 9.36M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 45.06M | 2.79M | 3.02M | 3.24M |
| DerivativeProductLiabilities | 42.49M | 0.00 | 0.00 | |
| NonCurrentDeferredLiabilities | 2.56M | 2.79M | 3.02M | 3.24M |
| NonCurrentDeferredRevenue | 2.56M | 2.79M | 3.02M | 3.24M |
| CurrentLiabilities | 11.53M | 9.22M | 8.05M | 6.12M |
| CurrentDeferredLiabilities | 226.00K | 226.00K | 226.00K | 226.00K |
| CurrentDeferredRevenue | 226.00K | 226.00K | 226.00K | 226.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 265.00K | 1.00M | 1.19M | 1.22M |
| PayablesAndAccruedExpenses | 11.04M | 7.99M | 6.63M | 4.67M |
| CurrentAccruedExpenses | 2.86M | 2.37M | 2.77M | 1.92M |
| Payables | 8.19M | 5.62M | 3.86M | 2.76M |
| AccountsPayable | 8.19M | 5.62M | 3.86M | 2.76M |
| TotalAssets | 24.96M | 22.68M | 39.37M | 55.48M |
| TotalNonCurrentAssets | 11.00K | 23.00K | 25.00K | 48.00K |
| OtherNonCurrentAssets | 1.00K | 1.00K | 1.00K | 10.00K |
| NetPPE | 10.00K | 22.00K | 24.00K | 38.00K |
| AccumulatedDepreciation | -74.00K | -62.00K | -46.00K | -32.00K |
| GrossPPE | 84.00K | 84.00K | 70.00K | 70.00K |
| MachineryFurnitureEquipment | 84.00K | 84.00K | 70.00K | 70.00K |
| CurrentAssets | 24.95M | 22.66M | 39.35M | 55.43M |
| OtherCurrentAssets | 178.00K | 401.00K | 40.00K | 35.00K |
| PrepaidAssets | 1.67M | 1.42M | 521.00K | 297.00K |
| Receivables | 1.76M | 18.00K | 29.00K | 28.00K |
| AccountsReceivable | 1.76M | 18.00K | 29.00K | 28.00K |
| CashCashEquivalentsAndShortTermInvestments | 21.34M | 20.82M | 38.76M | 55.07M |
| CashAndCashEquivalents | 21.34M | 20.82M | 38.76M | 55.07M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -29.79M | -17.95M | -16.29M | -19.49M |
| IssuanceOfCapitalStock | 33.98M | 0.00 | 0.00 | 55.04M |
| CapitalExpenditure | -14.00K | |||
| EndCashPosition | 21.34M | 20.82M | 38.76M | 55.07M |
| BeginningCashPosition | 20.82M | 38.76M | 55.07M | 19.02M |
| EffectOfExchangeRateChanges | -19.00K | 10.00K | -19.00K | -28.00K |
| ChangesInCash | 536.00K | -17.95M | -16.29M | 36.07M |
| FinancingCashFlow | 33.98M | 0.00 | 0.00 | 55.56M |
| CashFlowFromContinuingFinancingActivities | 33.98M | 0.00 | 0.00 | 55.56M |
| ProceedsFromStockOptionExercised | 0.00 | 519.00K | ||
| NetCommonStockIssuance | 33.98M | 0.00 | 0.00 | 55.04M |
| CommonStockIssuance | 33.98M | 0.00 | 0.00 | 55.04M |
| InvestingCashFlow | -3.65M | -14.00K | 0.00 | 0.00 |
| CashFlowFromContinuingInvestingActivities | -3.65M | -14.00K | 0.00 | 0.00 |
| NetBusinessPurchaseAndSale | -3.65M | 0.00 | ||
| PurchaseOfBusiness | -3.65M | 0.00 | ||
| NetPPEPurchaseAndSale | 0.00 | -14.00K | 0.00 | 0.00 |
| PurchaseOfPPE | 0.00 | -14.00K | 0.00 | 0.00 |
| OperatingCashFlow | -29.79M | -17.93M | -16.29M | -19.49M |
| CashFlowFromContinuingOperatingActivities | -29.79M | -17.93M | -16.29M | -19.49M |
| ChangeInWorkingCapital | -6.57M | -301.00K | 1.48M | -3.59M |
| ChangeInOtherWorkingCapital | -226.00K | -226.00K | -226.00K | -226.00K |
| ChangeInOtherCurrentAssets | 0.00 | 9.00K | 0.00 | |
| ChangeInPayablesAndAccruedExpense | -4.57M | 1.17M | 1.93M | -3.91M |
| ChangeInAccruedExpense | -5.22M | -585.00K | 828.00K | -1.83M |
| ChangeInPayable | 646.00K | 1.76M | 1.10M | -2.08M |
| ChangeInAccountPayable | 646.00K | 1.76M | 1.10M | -2.08M |
| ChangeInPrepaidAssets | -27.00K | -1.26M | -229.00K | 530.00K |
| ChangeInReceivables | -1.75M | 11.00K | -1.00K | 9.00K |
| OtherNonCashItems | 117.46M | |||
| StockBasedCompensation | 1.39M | 1.30M | 1.17M | 576.00K |
| DepreciationAmortizationDepletion | 12.00K | 16.00K | 14.00K | 14.00K |
| DepreciationAndAmortization | 12.00K | 16.00K | 14.00K | 14.00K |
| OperatingGainsLosses | 24.44M | -321.00K | ||
| GainLossOnInvestmentSecurities | 24.44M | -321.00K | ||
| NetIncomeFromContinuingOperations | -166.52M | -18.95M | -18.96M | -16.16M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for TRAW
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|